抗逆转录病毒治疗对HIV-1感染者外周血CD19^(+)B淋巴细胞的活化与凋亡的影响  

Effect of antiretroviral therapy on activation and apoptosis ofperipheral blood CD19 ^(+) B lymphocytes in HIV-1-infected people

作　　者：李建明 熊润松 彭丽珊[1] 王登嵘 杨洋[1] 刘显[1] 伍月榕 梁镕伊 梁淑家[4] 肖健[1,5] LI Jian-ming;XIONG Run-song;PENG Li-shan;WANG Deng-rong;YANG Yang;LIU Xian;WU Yue-rong;LIANG Rong-yi;LIANG Shu-jia;XIAO Jian(Department of Immunology,Guangxi University of Traditional Chinese Medicine,Nanning 530020,China;School of Public Management,Guangxi University of Traditional Chinese Medicine,Nanning 530020,China;Department of Endemic and Chronic Diseases Health Education,Wulong District CenteRfoRDisease Control and Prevention,Chongqing 408500,China;Department of AIDS Control and Prevention,Guangxi CenteRfoRDisease Control and Prevention,Nanning 530000,China;Guangxi Key Laboratory of Translational Medicine foRTreating High-Incidence Infectious Diseases with Integration of Traditional and Western Medicine,Guangxi University of Traditional Chinese Medicine,Nanning 530022,China)

机构地区：[1]广西中医药大学免疫学教研室,南宁市530020 [2]广西中医药大学公共管理学院,南宁市530020 [3]重庆市武隆区疾病预防控制中心地方病与慢性病健康教育科,重庆市408500 [4]广西壮族自治区疾病预防控制中心艾滋病防制科,南宁市530000 [5]广西中医药大学广西高发传染病中西医结合转化医学重点实验室,南宁市530022

出　　处：《广西医学》2021年第13期1529-1533,共5页Guangxi Medical Journal

基　　金：国家自然科学基金(81560547、81860780);广西中医药大学一流学科建设开放课题(2018XK064、2019XK157、2019XK143)。

摘　　要：目的探讨抗逆转录病毒治疗(ART)对HIV-1感染者CD19^(+)B淋巴细胞水平及其CD38、CD95和程序性死亡受体1(PD-1)水平的影响。方法根据是否行ART,将101例HIV-1感染患者分为未治疗组73例和治疗组28例,另选取30例健康者作为健康对照组。采用流式细胞术检测3组外周血CD19^(+)B淋巴细胞水平及其CD38、CD95和PD-1的水平。并分析治疗组、未治疗组中上述指标之间的相关性。结果未治疗组、治疗组、健康对照组CD19^(+)B淋巴细胞水平依次升高,而该细胞中CD95水平依次降低(均P<0.05);健康对照组和治疗组CD19^(+)B淋巴细胞CD38的表达水平均低于未治疗组(均P<0.05),而治疗组和健康对照组差异无统计学意义(P>0.05);未治疗组和治疗组CD19^(+)B淋巴细胞PD-1的表达水平均高于健康对照组(均P<0.05),而治疗组与未治疗组差异无统计学意义(P>0.05)。治疗组中,外周血CD19^(+)B淋巴细胞及CD19^(+)B淋巴细胞上的CD38、PD-1、CD95表达水平之间均不存在相关性(均P>0.05);在未治疗组中仅有CD38与CD95间的表达水平呈正相关(P<0.05)。结论ART可能通过影响HIV-1感染者CD19^(+)B淋巴细胞中CD38与CD95(而非PD-1)的表达及两者的相互作用,增强CD19^(+)B淋巴细胞的活化而抑制其凋亡,从而对HIV-1感染者的体液免疫功能发挥一定的修复作用。Objective To investigate the effect of antiretroviral therapy(ART)on the level of CD19^(+)B lymphocytes as well as the levels of CD38,CD95 and programmed cell death 1(PD-1)in the cells among HIV-1-infected people.Methods According to whetheRART was performed,101 patients with HIV-1 infection were divided into 73 cases in the non-treatment group and 28 cases in the treatment group,and anotheR30 healthy individuals were enrolled as healthy control group.Flow cytometry was employed to detect the level of peripheral blood CD19^(+)B lymphocytes as well as the levels of CD38,CD95 and PD-1 in the cells.In addition,the correlation between the indices described above was analyzed in the non-treatment and treatment groups.Results The level of CD19^(+)B lymphocytes increased and the level of CD95 in CD19^(+)B lymphocytes decreased in the sequence of the non-treatment group,the treatment group and the healthy control group(all P<0.05);the healthy control and treatment groups exhibited a loweRexpression level of CD38 in CD19^(+)B lymphocytes than the non-treatment group(all P<0.05),whereas no statistically significant difference was found between the treatment group and the healthy control group(P>0.05).The non-treatment and treatment groups yielded a higheRexpression level of PD-1 in CD19^(+)B lymphocytes than the healthy control group(all P<0.05),whereas no statistically significant difference was observed between the treatment group and the non-treatment group(P>0.05).In the treatment group,no correlation was found between the expression level of peripheral blood CD19^(+)B lymphocytes and the expression level of CD38,PD-1 oRCD95 in CD19^(+)B lymphocytes(all P>0.05);in the non-treatment group,the positive correlation only existed between the expression levels of CD38 and CD95(P<0.05).Conclusion ART can increase the activation of CD19^(+)B lymphocytes and inhibit its apoptosis probably via affecting the expression of CD38 and CD95(otheRthan PD-1)in CD19^(+)B lymphocytes of HIV-1-infected people and theiRinteraction,thus exer

关 键 词：人类免疫免疫缺陷病毒1感染 B淋巴细胞 CD19 CD38 CD95 程序性死亡受体1 

分 类 号：R512.91[医药卫生—内科学]